Eric Wong, MD
Neurology · Boston, MANPI 1437179199
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $28,300 of the $41,917 with a category attached, or 67.5%. E.r. Squibb & Sons, L.L.C. accounts for 61.5% of it on its own, with 10 other manufacturers making up the rest. 2025 is the largest year on record at $28,972, more than ten times the $514 reported in 2019. Among neurology clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 53 payments — averaging $790.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$26K
- Novocure Inc.$11K
- Pfizer$3K
- Telix Pharmaceuticals$1K
- Agios Pharmaceuticals, Inc.$185
- Merck$146
- plus $306 from 5 others
Across 26 payments — averaging $11,397 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novocure GmbH$231K
- Novocure Inc.$65K
What the payments were for
- Consulting fees$28,30068%
- Speaking & faculty fees$7,50018%
- Travel & lodging$2,5766%
- Food & beverage$3,5418%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 1 | $25,800 |
| Novocure Inc. | 30 | $11,229 |
| Pfizer | 5 | $3,029 |
| Telix Pharmaceuticals | 9 | $1,222 |
| Agios Pharmaceuticals, Inc. | 1 | $185 |
| Merck | 1 | $146 |
| Kyowa Kirin, Inc. | 1 | $124 |
| Johnson & Johnson | 1 | $63 |
| AbbVie | 2 | $62 |
| Biogen | 1 | $42 |
| Novo Nordisk | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$41,917 in reported general payments places this provider in the 90th percentile of 761 neurology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enoxaparin Sodium | 11 | $8,726 |
| Lamotrigine | 31 | $955 |
| Celecoxib | 14 | $759 |
| Levetiracetam | 33 | $704 |
| Dexamethasone | 34 | $389 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 32 | $293 |
| AmantadineAmantadine Hcl | 12 | $204 |
| Ondansetron Hcl | 15 | $67 |
| Metformin Hcl | 14 | $63 |
Paid to pharmacies, not to this prescriber.
Other neurology in Boston
- Christopher WrightBoston$2.5M
- Thomas ScammellBoston$617K
- Alfred SandrockBoston$490K
- Pushpa NarayanaswamiBoston$420K
- Roy FreemanBoston$390K
- Michael LevyBoston$387K
- Leeann BurtonBoston$325K
- Ilena GeorgeBoston$316K
- Andrew BudsonBoston$304K
- Denis BalabanBoston$297K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.